Prof. David Denning, FRCP FRCPath DCH FMedSci
David Denning is an infectious diseases clinician with expertise in fungal diseases. Now retired from clinical practice, he is currently a Professor of Infectious Diseases in Global Health at the University of Manchester. He is also the Founding President and Chief Executive of the Global Action Fund for Fungal Infections and the Executive Director of Leading International Fungal Education. He founded two University spinout biotechnology companies – F2G Ltd (antifungal drug discovery and development) and Myconostica Ltd (molecular diagnostic tests for fungi).
Professor Denning’s research efforts are directed at improving clinical outcomes for patients with fungal infections and more recently fungal allergy. He has published more than 600 papers, books and book chapters and lectures worldwide. In addition to serving on the advisory board of TFF Pharmaceuticals, he acts or has recently acted as a consultant to Pulmatrix, Pulmocide, Zambon, Biosergen, Bright Angel Therapeutics, Cipla, Pfizer and Fujifilm.
Professor Denning graduated from Guys Hospital in London in 1980 and was trained in London and Glasgow in internal medicine and infectious diseases. He completed additional research training at the MRC Clinical Research Centre in Harrow, UK as well as a three-year fellowship at Stanford University, Santa Clara Valley Medical Center.